Use of Ceftaroline Fosamil in Osteomyelitis: CAPTURE Study Experience View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Leonard B. Johnson, Ananthakrishnan Ramani, David J. Guervil

ABSTRACT

BACKGROUND: Osteomyelitis is often challenging to treat. This analysis examined the clinical experience of patients with gram-positive osteomyelitis treated with ceftaroline fosamil in the phase 4 Clinical Assessment Program and Teflaro® Utilization Registry (CAPTURE) study. METHODS: Data including patient demographics, past illnesses, risk factors, disease characteristics, antibiotic use, pathogens isolated, and clinical outcome were collected between September 2013 and February 2015 by review of randomly ordered patient charts from participating sites in the United States. Clinical success was defined as discontinuation of ceftaroline fosamil following clinical cure with no further need for antibiotics or clinical improvement with switch to another antibiotic treatment. RESULTS: A total of 150 patients with gram-positive osteomyelitis were treated with ceftaroline fosamil. Most patients (117/150; 78.0%) were treated with 600 mg ceftaroline fosamil per dose; 143/150 patients (95.3%) received a dose every 12 h. The majority (89/150 patients; 59.3%) had been previously diagnosed with diabetes mellitus or peripheral arterial disease. Osteomyelitis was associated with hardware in 32/150 patients (21.3%). Methicillin-resistant and methicillin-susceptible Staphylococcus aureus (MRSA; MSSA) were the most commonly isolated pathogens, observed in 93/150 (62.0%) and 21/150 (14.0%) patients, respectively. Clinical success with ceftaroline fosamil therapy was observed in 139/150 (92.7%) patients overall, 81/89 (91.0%) patients with diabetes or peripheral arterial disease, and 18/20 (90.0%) patients who had hardware implanted before ceftaroline fosamil therapy (none had hardware removed during therapy). Patients who received prior antibiotic therapy or ceftaroline fosamil as monotherapy experienced clinical success rates of 93.9% (107/114) and 91% (91/100), respectively. Among patients who received concurrent antibiotic therapy, the clinical success rate was 96.0% (48/50). Patients who were infected with MRSA or MSSA had clinical success rates of 92.5% (86/93) and 100% (21/21), respectively. A total of 2/150 (1.3%) patients discontinued ceftaroline fosamil therapy because of adverse events. CONCLUSIONS: Clinical success rates with ceftaroline fosamil were high in patients with gram-positive osteomyelitis, including those with diabetes or peripheral arterial disease and those with MRSA or MSSA. More... »

PAGES

183

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12879-019-3791-z

DOI

http://dx.doi.org/10.1186/s12879-019-3791-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112291990

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30791894


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Bacterial Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cephalosporins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Methicillin-Resistant Staphylococcus aureus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multicenter Studies as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteomyelitis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Registries", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Staphylococcal Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Staphylococcus aureus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Wayne State University", 
          "id": "https://www.grid.ac/institutes/grid.254444.7", 
          "name": [
            "Ascension St. John Hospital and Medical Center and Wayne State University School of Medicine, 19251 Mack Avenue, Suite 340, 48236, Grosse Pointe Woods, MI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Johnson", 
        "givenName": "Leonard B.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Memorial Sloan Kettering Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Columbia Memorial Hospital, Hudson, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ramani", 
        "givenName": "Ananthakrishnan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Texas Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.416986.4", 
          "name": [
            "Memorial Hermann-Texas Medical Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guervil", 
        "givenName": "David J.", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1002/14651858.cd004439.pub3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001508849"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.00149-08", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003739910"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.02371-13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005425581"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/pmj.76.898.479", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005837094"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/pmj.76.898.479", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005837094"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.00019-10", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010982224"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ipc.0b013e31825b2110", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020379231"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ipc.0b013e31825b2110", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020379231"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ipc.0b013e31825b2110", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020379231"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(04)16727-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021880965"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1086/380449", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023173418"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/jcpt.12062", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024017425"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.00498-15", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031644308"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1056-8727(99)00065-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034150026"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/cid/cir842", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036287688"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ipc.0000000000000191", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036877321"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ipc.0000000000000191", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036877321"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/phar.1435", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037658640"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1086/657313", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038827862"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jac/dkq254", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040227277"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/dmrr.2624", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044781654"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1086/655827", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045803136"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jac/dkg186", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047112445"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ipc.0b013e318276959f", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047407134"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ipc.0b013e318276959f", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047407134"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jac/dkq255", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050380858"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2106/jbjs.n.01350", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1068903990"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2106/jbjs.n.01350", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1068903990"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2106/jbjs.n.01350", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1068903990"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2146/ajhp130474", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069100425"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2146/ajhp130474", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069100425"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2146/ajhp130474", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069100425"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2146/ajhp130474", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069100425"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078470914", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: Osteomyelitis is often challenging to treat. This analysis examined the clinical experience of patients with gram-positive osteomyelitis treated with ceftaroline fosamil in the phase 4 Clinical Assessment Program and Teflaro\u00ae Utilization Registry (CAPTURE) study.\nMETHODS: Data including patient demographics, past illnesses, risk factors, disease characteristics, antibiotic use, pathogens isolated, and clinical outcome were collected between September 2013 and February 2015 by review of randomly ordered patient charts from participating sites in the United States. Clinical success was defined as discontinuation of ceftaroline fosamil following clinical cure with no further need for antibiotics or clinical improvement with switch to another antibiotic treatment.\nRESULTS: A total of 150 patients with gram-positive osteomyelitis were treated with ceftaroline fosamil. Most patients (117/150; 78.0%) were treated with 600\u2009mg ceftaroline fosamil per dose; 143/150 patients (95.3%) received a dose every 12\u2009h. The majority (89/150 patients; 59.3%) had been previously diagnosed with diabetes mellitus or peripheral arterial disease. Osteomyelitis was associated with hardware in 32/150 patients (21.3%). Methicillin-resistant and methicillin-susceptible Staphylococcus aureus (MRSA; MSSA) were the most commonly isolated pathogens, observed in 93/150 (62.0%) and 21/150 (14.0%) patients, respectively. Clinical success with ceftaroline fosamil therapy was observed in 139/150 (92.7%) patients overall, 81/89 (91.0%) patients with diabetes or peripheral arterial disease, and 18/20 (90.0%) patients who had hardware implanted before ceftaroline fosamil therapy (none had hardware removed during therapy). Patients who received prior antibiotic therapy or ceftaroline fosamil as monotherapy experienced clinical success rates of 93.9% (107/114) and 91% (91/100), respectively. Among patients who received concurrent antibiotic therapy, the clinical success rate was 96.0% (48/50). Patients who were infected with MRSA or MSSA had clinical success rates of 92.5% (86/93) and 100% (21/21), respectively. A total of 2/150 (1.3%) patients discontinued ceftaroline fosamil therapy because of adverse events.\nCONCLUSIONS: Clinical success rates with ceftaroline fosamil were high in patients with gram-positive osteomyelitis, including those with diabetes or peripheral arterial disease and those with MRSA or MSSA.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12879-019-3791-z", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024946", 
        "issn": [
          "1471-2334"
        ], 
        "name": "BMC Infectious Diseases", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "name": "Use of Ceftaroline Fosamil in Osteomyelitis: CAPTURE Study Experience", 
    "pagination": "183", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "6413cc9b63a3f9ec6768e953fa43466f595d03104658931bbe10aba99292fbee"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30791894"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100968551"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12879-019-3791-z"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112291990"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12879-019-3791-z", 
      "https://app.dimensions.ai/details/publication/pub.1112291990"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:53", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000371_0000000371/records_130805_00000006.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12879-019-3791-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12879-019-3791-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12879-019-3791-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12879-019-3791-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12879-019-3791-z'


 

This table displays all metadata directly associated to this object as RDF triples.

232 TRIPLES      21 PREDICATES      72 URIs      40 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12879-019-3791-z schema:about N03eca38d465d40d484548ca3ed187033
2 N13048fc27a094dc780e6c93035feff4a
3 N1520852941be4f27b44898e6d85126ee
4 N1c73e768c07f4b6f989f31a8a0723157
5 N31eb8f62050c42659efb3a16a84577dc
6 N3b9603eeb603403fb0455a067346e2a5
7 N458165bd72f64ea0a16317bc519b54a6
8 N50acdb48811c4987bcb7efad2d774a32
9 N8c04593a1fd340819296b0eaed82f89a
10 N99555ace73ef42f68f683ee98b36af73
11 N9d33b021a9b542179cf39a0bc243e793
12 Nb9d05124ddbc4357a04a9a86f4346cbf
13 Ncbde9bfb64764fc59e5900f51313662f
14 Ndf6e3971aed54505bb2b2f7d48328109
15 Ne1b7f89ebebb42a190cc17342c357d03
16 Ne3f46774c6b0482686a0cf30488203af
17 Neac247bfb9b64e20b21085e516a1c4f8
18 Nf956d0414df94d9e99a43717ee282e0a
19 Nfea220f53383471eac6523a7213b417e
20 anzsrc-for:11
21 anzsrc-for:1103
22 schema:author N4c9d0431dc554ce4b9a7ff42b6d573a5
23 schema:citation https://app.dimensions.ai/details/publication/pub.1078470914
24 https://doi.org/10.1002/14651858.cd004439.pub3
25 https://doi.org/10.1002/dmrr.2624
26 https://doi.org/10.1002/phar.1435
27 https://doi.org/10.1016/s0140-6736(04)16727-5
28 https://doi.org/10.1016/s1056-8727(99)00065-3
29 https://doi.org/10.1086/380449
30 https://doi.org/10.1086/655827
31 https://doi.org/10.1086/657313
32 https://doi.org/10.1093/cid/cir842
33 https://doi.org/10.1093/jac/dkg186
34 https://doi.org/10.1093/jac/dkq254
35 https://doi.org/10.1093/jac/dkq255
36 https://doi.org/10.1097/ipc.0000000000000191
37 https://doi.org/10.1097/ipc.0b013e31825b2110
38 https://doi.org/10.1097/ipc.0b013e318276959f
39 https://doi.org/10.1111/jcpt.12062
40 https://doi.org/10.1128/aac.00019-10
41 https://doi.org/10.1128/aac.00149-08
42 https://doi.org/10.1128/aac.00498-15
43 https://doi.org/10.1128/aac.02371-13
44 https://doi.org/10.1136/pmj.76.898.479
45 https://doi.org/10.2106/jbjs.n.01350
46 https://doi.org/10.2146/ajhp130474
47 schema:datePublished 2019-12
48 schema:datePublishedReg 2019-12-01
49 schema:description BACKGROUND: Osteomyelitis is often challenging to treat. This analysis examined the clinical experience of patients with gram-positive osteomyelitis treated with ceftaroline fosamil in the phase 4 Clinical Assessment Program and Teflaro® Utilization Registry (CAPTURE) study. METHODS: Data including patient demographics, past illnesses, risk factors, disease characteristics, antibiotic use, pathogens isolated, and clinical outcome were collected between September 2013 and February 2015 by review of randomly ordered patient charts from participating sites in the United States. Clinical success was defined as discontinuation of ceftaroline fosamil following clinical cure with no further need for antibiotics or clinical improvement with switch to another antibiotic treatment. RESULTS: A total of 150 patients with gram-positive osteomyelitis were treated with ceftaroline fosamil. Most patients (117/150; 78.0%) were treated with 600 mg ceftaroline fosamil per dose; 143/150 patients (95.3%) received a dose every 12 h. The majority (89/150 patients; 59.3%) had been previously diagnosed with diabetes mellitus or peripheral arterial disease. Osteomyelitis was associated with hardware in 32/150 patients (21.3%). Methicillin-resistant and methicillin-susceptible Staphylococcus aureus (MRSA; MSSA) were the most commonly isolated pathogens, observed in 93/150 (62.0%) and 21/150 (14.0%) patients, respectively. Clinical success with ceftaroline fosamil therapy was observed in 139/150 (92.7%) patients overall, 81/89 (91.0%) patients with diabetes or peripheral arterial disease, and 18/20 (90.0%) patients who had hardware implanted before ceftaroline fosamil therapy (none had hardware removed during therapy). Patients who received prior antibiotic therapy or ceftaroline fosamil as monotherapy experienced clinical success rates of 93.9% (107/114) and 91% (91/100), respectively. Among patients who received concurrent antibiotic therapy, the clinical success rate was 96.0% (48/50). Patients who were infected with MRSA or MSSA had clinical success rates of 92.5% (86/93) and 100% (21/21), respectively. A total of 2/150 (1.3%) patients discontinued ceftaroline fosamil therapy because of adverse events. CONCLUSIONS: Clinical success rates with ceftaroline fosamil were high in patients with gram-positive osteomyelitis, including those with diabetes or peripheral arterial disease and those with MRSA or MSSA.
50 schema:genre research_article
51 schema:inLanguage en
52 schema:isAccessibleForFree true
53 schema:isPartOf N4bb72e65d83d4f14bd37cf9da5e53a18
54 Nd5a12ff58bdc462c9a0f6940cd69412e
55 sg:journal.1024946
56 schema:name Use of Ceftaroline Fosamil in Osteomyelitis: CAPTURE Study Experience
57 schema:pagination 183
58 schema:productId N09774a9945ae412ab623da41cf823359
59 N0cd0bbb4228e47feb1bdc743ccd5d7d8
60 N9a98d8275fb04fafbb89b97d3d1fccb8
61 Na7c3036a2d05466c9217ae4992ed6ce0
62 Ncc10fa5b90e6446da6fc9d8b25ce7345
63 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112291990
64 https://doi.org/10.1186/s12879-019-3791-z
65 schema:sdDatePublished 2019-04-11T13:53
66 schema:sdLicense https://scigraph.springernature.com/explorer/license/
67 schema:sdPublisher Nb241aa0b4f4e4d5abc3fed519186d911
68 schema:url https://link.springer.com/10.1186%2Fs12879-019-3791-z
69 sgo:license sg:explorer/license/
70 sgo:sdDataset articles
71 rdf:type schema:ScholarlyArticle
72 N03eca38d465d40d484548ca3ed187033 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Female
74 rdf:type schema:DefinedTerm
75 N09774a9945ae412ab623da41cf823359 schema:name dimensions_id
76 schema:value pub.1112291990
77 rdf:type schema:PropertyValue
78 N0cd0bbb4228e47feb1bdc743ccd5d7d8 schema:name nlm_unique_id
79 schema:value 100968551
80 rdf:type schema:PropertyValue
81 N13048fc27a094dc780e6c93035feff4a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Retrospective Studies
83 rdf:type schema:DefinedTerm
84 N1520852941be4f27b44898e6d85126ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Middle Aged
86 rdf:type schema:DefinedTerm
87 N1c73e768c07f4b6f989f31a8a0723157 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Osteomyelitis
89 rdf:type schema:DefinedTerm
90 N31eb8f62050c42659efb3a16a84577dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Aged
92 rdf:type schema:DefinedTerm
93 N3b9603eeb603403fb0455a067346e2a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Risk Factors
95 rdf:type schema:DefinedTerm
96 N458165bd72f64ea0a16317bc519b54a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Young Adult
98 rdf:type schema:DefinedTerm
99 N4bb72e65d83d4f14bd37cf9da5e53a18 schema:issueNumber 1
100 rdf:type schema:PublicationIssue
101 N4c0038ba082b4a57b20ba9420ce2bfd8 schema:affiliation https://www.grid.ac/institutes/grid.254444.7
102 schema:familyName Johnson
103 schema:givenName Leonard B.
104 rdf:type schema:Person
105 N4c9d0431dc554ce4b9a7ff42b6d573a5 rdf:first N4c0038ba082b4a57b20ba9420ce2bfd8
106 rdf:rest Ne96c79978d9a41078b86c86d8b0bc444
107 N50acdb48811c4987bcb7efad2d774a32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Cephalosporins
109 rdf:type schema:DefinedTerm
110 N8c04593a1fd340819296b0eaed82f89a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Staphylococcus aureus
112 rdf:type schema:DefinedTerm
113 N971e25a4e48e4e859a6a4ee5df7d14b5 schema:affiliation https://www.grid.ac/institutes/grid.51462.34
114 schema:familyName Ramani
115 schema:givenName Ananthakrishnan
116 rdf:type schema:Person
117 N99555ace73ef42f68f683ee98b36af73 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Adolescent
119 rdf:type schema:DefinedTerm
120 N9a98d8275fb04fafbb89b97d3d1fccb8 schema:name pubmed_id
121 schema:value 30791894
122 rdf:type schema:PropertyValue
123 N9d33b021a9b542179cf39a0bc243e793 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Aged, 80 and over
125 rdf:type schema:DefinedTerm
126 Na7c3036a2d05466c9217ae4992ed6ce0 schema:name doi
127 schema:value 10.1186/s12879-019-3791-z
128 rdf:type schema:PropertyValue
129 Nb241aa0b4f4e4d5abc3fed519186d911 schema:name Springer Nature - SN SciGraph project
130 rdf:type schema:Organization
131 Nb9d05124ddbc4357a04a9a86f4346cbf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Humans
133 rdf:type schema:DefinedTerm
134 Nc468f7d2e5a14091aa225338e4ab8626 schema:affiliation https://www.grid.ac/institutes/grid.416986.4
135 schema:familyName Guervil
136 schema:givenName David J.
137 rdf:type schema:Person
138 Ncbc5a97f588345e6ac2ff1a9cb9ef012 rdf:first Nc468f7d2e5a14091aa225338e4ab8626
139 rdf:rest rdf:nil
140 Ncbde9bfb64764fc59e5900f51313662f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Male
142 rdf:type schema:DefinedTerm
143 Ncc10fa5b90e6446da6fc9d8b25ce7345 schema:name readcube_id
144 schema:value 6413cc9b63a3f9ec6768e953fa43466f595d03104658931bbe10aba99292fbee
145 rdf:type schema:PropertyValue
146 Nd5a12ff58bdc462c9a0f6940cd69412e schema:volumeNumber 19
147 rdf:type schema:PublicationVolume
148 Ndf6e3971aed54505bb2b2f7d48328109 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Adult
150 rdf:type schema:DefinedTerm
151 Ne1b7f89ebebb42a190cc17342c357d03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Registries
153 rdf:type schema:DefinedTerm
154 Ne3f46774c6b0482686a0cf30488203af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Multicenter Studies as Topic
156 rdf:type schema:DefinedTerm
157 Ne96c79978d9a41078b86c86d8b0bc444 rdf:first N971e25a4e48e4e859a6a4ee5df7d14b5
158 rdf:rest Ncbc5a97f588345e6ac2ff1a9cb9ef012
159 Neac247bfb9b64e20b21085e516a1c4f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Anti-Bacterial Agents
161 rdf:type schema:DefinedTerm
162 Nf956d0414df94d9e99a43717ee282e0a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Methicillin-Resistant Staphylococcus aureus
164 rdf:type schema:DefinedTerm
165 Nfea220f53383471eac6523a7213b417e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Staphylococcal Infections
167 rdf:type schema:DefinedTerm
168 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
169 schema:name Medical and Health Sciences
170 rdf:type schema:DefinedTerm
171 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
172 schema:name Clinical Sciences
173 rdf:type schema:DefinedTerm
174 sg:journal.1024946 schema:issn 1471-2334
175 schema:name BMC Infectious Diseases
176 rdf:type schema:Periodical
177 https://app.dimensions.ai/details/publication/pub.1078470914 schema:CreativeWork
178 https://doi.org/10.1002/14651858.cd004439.pub3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001508849
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1002/dmrr.2624 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044781654
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1002/phar.1435 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037658640
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1016/s0140-6736(04)16727-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021880965
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1016/s1056-8727(99)00065-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034150026
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1086/380449 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023173418
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1086/655827 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045803136
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1086/657313 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038827862
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1093/cid/cir842 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036287688
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1093/jac/dkg186 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047112445
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1093/jac/dkq254 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040227277
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1093/jac/dkq255 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050380858
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1097/ipc.0000000000000191 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036877321
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1097/ipc.0b013e31825b2110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020379231
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1097/ipc.0b013e318276959f schema:sameAs https://app.dimensions.ai/details/publication/pub.1047407134
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1111/jcpt.12062 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024017425
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1128/aac.00019-10 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010982224
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1128/aac.00149-08 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003739910
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1128/aac.00498-15 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031644308
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1128/aac.02371-13 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005425581
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1136/pmj.76.898.479 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005837094
219 rdf:type schema:CreativeWork
220 https://doi.org/10.2106/jbjs.n.01350 schema:sameAs https://app.dimensions.ai/details/publication/pub.1068903990
221 rdf:type schema:CreativeWork
222 https://doi.org/10.2146/ajhp130474 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069100425
223 rdf:type schema:CreativeWork
224 https://www.grid.ac/institutes/grid.254444.7 schema:alternateName Wayne State University
225 schema:name Ascension St. John Hospital and Medical Center and Wayne State University School of Medicine, 19251 Mack Avenue, Suite 340, 48236, Grosse Pointe Woods, MI, USA
226 rdf:type schema:Organization
227 https://www.grid.ac/institutes/grid.416986.4 schema:alternateName Texas Medical Center
228 schema:name Memorial Hermann-Texas Medical Center, Houston, TX, USA
229 rdf:type schema:Organization
230 https://www.grid.ac/institutes/grid.51462.34 schema:alternateName Memorial Sloan Kettering Cancer Center
231 schema:name Columbia Memorial Hospital, Hudson, NY, USA
232 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...